Jane Street Group LLC Sells 115,722 Shares of Seer, Inc. (NASDAQ:SEER)

Jane Street Group LLC decreased its position in Seer, Inc. (NASDAQ:SEER) by 37.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 190,317 shares of the company’s stock after selling 115,722 shares during the quarter. Jane Street Group LLC owned 0.31% of Seer worth $375,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Quadrature Capital Ltd lifted its position in Seer by 301.7% in the third quarter. Quadrature Capital Ltd now owns 57,088 shares of the company’s stock valued at $112,000 after purchasing an additional 42,875 shares during the last quarter. GSA Capital Partners LLP lifted its position in Seer by 194.9% in the third quarter. GSA Capital Partners LLP now owns 127,868 shares of the company’s stock valued at $252,000 after purchasing an additional 84,515 shares during the last quarter. Palumbo Wealth Management LLC lifted its position in Seer by 15.1% in the third quarter. Palumbo Wealth Management LLC now owns 122,292 shares of the company’s stock valued at $241,000 after purchasing an additional 16,001 shares during the last quarter. Point72 DIFC Ltd purchased a new position in shares of Seer during the second quarter valued at approximately $35,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Seer during the second quarter valued at approximately $133,000. Institutional investors own 75.20% of the company’s stock.

Seer Stock Performance

SEER opened at $2.41 on Thursday. Seer, Inc. has a 52-week low of $1.51 and a 52-week high of $2.63. The stock has a market capitalization of $142.11 million, a PE ratio of -1.85 and a beta of 1.57. The stock’s 50 day moving average price is $2.34 and its 200-day moving average price is $1.98.

Seer Company Profile

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.